Investigating the role of platelets in autoimmune diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the interactions between activated platelets and immune cells in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases such as systemic scleroderma, ANCA vasculitis, inflammatory myositis, and Gougerot-Sjögren syndrome. The research focuses on how these interactions may contribute to the pathophysiology of these conditions, particularly in cases of high disease activity. By comparing platelet-immune cell interactions across different autoimmune diseases, the study seeks to enhance understanding of the immune dysregulation associated with SLE and similar disorders.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients between 18 and 70 years of age
* Patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary)
* Patient able to understand the aims and risks of research
* Patient having signed and dated an informed consent form
* Patient for whom the diagnosis of at least one of the following pathologies has been confirmed:
* Systemic lupus erythematosus meeting ACR/EULAR 20195 classification criteria.
* Systemic scleroderma meeting ACR/EULAR 20136 classification criteria.
* ANCA vasculitis according to EULAR/ACR 2022.7-9 classification criteria.
* Inflammatory myositis according to EULAR/ACR 201710 classification criteria.
* Gougerot-Sjögren syndrome according to EULAR/ACR 2016 classification criteria11.
* Rheumatoid arthritis according to ACR/EULAR 201012 classification criteria.

Exclusion Criteria:

* Patient in exclusion period (determined by a previous or current study)
* Inability to give patient informed consent (patient in emergency or immediate life-threatening situation)
* Patient under court protection
* Patient under guardianship or curatorship

Where it's running

• Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre - Service de rhumatologie
  Strasbourg, France, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• ABBV-519 in adults with SLE or RA: safety and how the drug moves through the body after IV and subcutaneous doses

  This early study tests how ABBV-519 behaves in the body and its safety for adults with SLE or RA after single escalating doses.

  Recruiting at 15 sites Phase 1 AbbVie · Anniston, Alabama and 14 other locations · NCT07607964

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

• MK-1045 for people with lupus or rheumatoid arthritis

  This research tests the experimental medicine MK-1045 to see if it is safe and tolerable in adults with lupus or rheumatoid arthritis.

  Recruiting at 20 sites Phase 1 Merck Sharp & Dohme LLC · Southport, Queensland and 20 other locations · NCT07363590

• LY4298445 in healthy adults and people with lupus or rheumatoid arthritis

  This trial will test whether LY4298445 is safe and well tolerated in healthy adults and in people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Brisbane and 9 other locations · NCT07276958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.